ebulised frusemide to imporve the sensation and unpleasant feeling of dyspnoea in patients with advanced diseases and breathlessness refractory to optimal standard management
- Conditions
- Dyspnoea in advanced diseasesRespiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12612000778886
- Lead Sponsor
- Dr Maria Cristina Cigolini
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 45
Primary diagnosis of any irreversible disease. Prognosis of the disease needs to be less than 12 months.
-Refractory dyspnoea that is not reponsive to more establisehd therapies.
-Any concomitant disease but not rapidly deteriorating
-Willingness to give informed consent documented by the treating team and willingness to participate and comply with the study
-Unwilling/unable to give informed consent
-Unable to tolerate frusemide
-Rapid deterioration
-Hepatic encephalopathy
-Anuric renal failure
-Mental or cognitive disorder, unable to reliably self-report or consent
-Significant hypotension with the risk of further pronounced drop in blood pressure
-Currently receiving risperidone
-Significant history of gout
-Significant change in medication that may affect dyspnoea within the last 24 hours
-Hypersensitivity to frusemide or any inactive ingredient
-Actively receiving treatment for dyspnoea, for example pleural effusion drainage or blood transfusion
-Electrolyte disturbance
-Aversion/inability to fit mask
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of the sensation of dyspnoea measured by a Modified BORG scale[30 minutes and 60 minutes after the initiation of treatment];Change of the unpleasant feeling of dyspnoea measured by the anxiety section of a Hospital Anxiety and Depression Scale[At the end of each day during a 2 day treatment schedule]
- Secondary Outcome Measures
Name Time Method il[Nil]